Dr. Matulewicz on smoking status data in genitourinary cancer trials
In this video, Richard Matulewicz, MD, MS, discusses the background and findings of the study, “Persistent deficiencies in the measurement and reporting of tobacco use in contemporary genitourinary oncology clinical trials,” presented recently at the 2021 American Urological Association Annual Meeting. Matulewicz is an assistant professor in the department of urology at Memorial Sloan Kettering Cancer Center, New York City.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Cell therapy TARA-002 shows initial promise in NMIBC
April 9th 2024"This encouraging anti-tumor activity coupled with a favorable safety profile and mode of administration that is both convenient and familiar to urologists indicates that, if confirmed in future studies, TARA-002 could potentially play a meaningful role in NMIBC treatment in the future," says Timothy D. Lyon, MD.
